Of course, the biggest selling drug in the history of the world is a cholesterol-lowering pill. Many investors were attrated by the prospect of such a huge market opportunity.
You keep referring to clinical studies.
**NYR have not completed a single clinical study**
Maybe you are talking about pre-clinical studies. In any case, the current brain injury drug candidate was only selected last year after issues with previous versions.
That's been a pattern with NYR since I first invested in Dec 2020. Drug candidates for both programs getting switched out, delays with manufacturing and pre-clinical work, eventual shelving of the cholesterol-lowering program. So yes, investors clearly lack confidence in management, otherwise the MC would be much higher.
Also, you should delete your previous posts with blatantly incorrect information about both AGNs and NYRs drug candidates. Disc: I hold both NYR and AGN. I have far more confidence and optimism for the latter.
I'll leave this slide from the 2020 AGM here - right before I first invested. We've been delayed 2+ years on the brain injury program and the cholesterol-lowering program was shelved before ever entering the clinic (after an extra 2 years delays).
.
(20min delay)